Trials / Unknown
UnknownNCT05502393
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JS107 | JS107, i.v., q3w |
| DRUG | Toripalimab | Toripalimab i.v., q3w |
Timeline
- Start date
- 2022-07-26
- Primary completion
- 2024-07-31
- Completion
- 2024-12-31
- First posted
- 2022-08-16
- Last updated
- 2022-08-16
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05502393. Inclusion in this directory is not an endorsement.